TY  - JOUR
AU  - Holzgreve, Adrien
AU  - Unterrainer, Lena M
AU  - Tiling, Maximilian
AU  - Mansour, Nabeel
AU  - Spitzweg, Christine
AU  - Brendel, Matthias
AU  - Ricke, Jens
AU  - Unterrainer, Marcus
AU  - Kunz, Wolfgang G
AU  - Mehrens, Dirk
TI  - Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials.
JO  - Journal of nuclear medicine
VL  - 66
IS  - 7
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2025-01166
SP  - 1075-1081
PY  - 2025
N1  - 2025, 66 (7) 1075-1081
AB  - The recently published results of the NETTER-2 trial suggest the use of [177Lu]Lu-DOTATATE as a new standard of care in first-line therapy of patients with grade 2 or 3, well-differentiated, advanced gastroenteropancreatic neuroendocrine tumors. The NETTER-2 trial found superior median progression-free survival (22.8 mo vs. 8.5 mo) and similar adverse events and quality-of-life measures in patients treated with [177Lu]Lu-DOTATATE compared with octreotide long-acting release (LAR) alone. As [177Lu]Lu-DOTATATE therapy is associated with higher costs, we compared the cost-effectiveness of [177Lu]Lu-DOTATATE with that of octreotide LAR in this setting. Methods: A partitioned survival model was established for the trial duration of 36 mo as well as a lifetime horizon of 20 y. Progression-free survival and treatment regimens for each patient group were derived from the NETTER-2 trial. Information on overall survival as well as utilities for health states and utilities and costs of adverse events were obtained from the literature. Information on treatment costs was obtained from the Centers for Medicare and Medicaid Services. The willingness-to-pay threshold was set to 100,000 per quality−adjusted life−year (QALY). Results: [177Lu]Lu−DOTATATE was cost−effective during the trial duration, with an incremental QALY of 0.13 at a slightly higher cost (8,931), leading to an incremental cost-effectiveness ratio of 
KW  - GEPNET (Other)
KW  - NETTER-2 (Other)
KW  - cost-effectiveness analysis (Other)
KW  - neuroendocrine (Other)
KW  - oncology (Other)
KW  - radionuclide therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40473457
DO  - DOI:10.2967/jnumed.124.269416
UR  - https://inrepo02.dkfz.de/record/301887
ER  -